Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sheets

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics|March 3, 2012
Ethics: Put education ahead of new limitationsMichael Sheets
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Saxitoxin blocks L-type ICaZhi Su, Michael Sheets, Hideyuki Ishida, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 27, 2009
Nonanticoagulant heparin reduces myocyte Na+ and Ca2+ loading during simulated ischemia and decreases reperfusion injuryWilliam H Barry, Xiu Q Zhang, Michael E Halkos, et al.
Cancer Discovery|March 18, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Chandra Miduturu, Michael Sheets, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2013
Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humansErica K Evans, Richland Tester, Sharon Aslanian, et al.
Journal of Cardiovascular Pharmacology|April 18, 2007
Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppressionYung-Wu Chen, Morey L Smith, Michael Sheets, et al.
Molecular Cancer Therapeutics|April 12, 2014
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparingRobert Tjin Tham Sjin, Kwangho Lee, Annette O Walter, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
American Journal of Orthodontics and Dentofacial Orthopedics : Official Publication of the American Association of Orthodontists, Its Constituent Societies, and the American Board of Orthodontics|March 3, 2012
Ethics: Put education ahead of new limitationsMichael Sheets
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Saxitoxin blocks L-type ICaZhi Su, Michael Sheets, Hideyuki Ishida, et al.
American Journal of Physiology. Heart and Circulatory Physiology|October 27, 2009
Nonanticoagulant heparin reduces myocyte Na+ and Ca2+ loading during simulated ischemia and decreases reperfusion injuryWilliam H Barry, Xiu Q Zhang, Michael E Halkos, et al.
Cancer Discovery|March 18, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Chandra Miduturu, Michael Sheets, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 28, 2013
Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humansErica K Evans, Richland Tester, Sharon Aslanian, et al.
Journal of Cardiovascular Pharmacology|April 18, 2007
Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppressionYung-Wu Chen, Morey L Smith, Michael Sheets, et al.
Molecular Cancer Therapeutics|April 12, 2014
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparingRobert Tjin Tham Sjin, Kwangho Lee, Annette O Walter, et al.
Cancer Discovery|September 26, 2013
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLCAnnette O Walter, Robert Tjin Tham Sjin, Henry J Haringsma, et al.
Pageof 1